Nine More States Offer Medicaid Coverage for Breast and Cervical Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

WASHINGTON-Health and Human Services Secretary Tommy Thompson has given nine more states the go-ahead to extend Medicaid benefits to uninsured women diagnosed with cancer under the federal Breast and Cervical Cancer Prevention and Treatment Act of 2000.

WASHINGTON—Health and Human Services Secretary Tommy Thompson has given nine more states the go-ahead to extend Medicaid benefits to uninsured women diagnosed with cancer under the federal Breast and Cervical Cancer Prevention and Treatment Act of 2000. 

Alabama, Georgia, Iowa, Mississippi, Missouri, North Dakota, South Carolina, Virginia, and Washington join 19 previously approved states.

Articles in this issue
High-Dose IL-2 Is Standard in Advanced Renal Cell Cancer
RIT Safe, Effective in Elderly and Poor-Prognosis Patients
FDA Approves Xeloda/Taxotere Combination for Advanced Breast Cancer
ODAC Recommends Approval of Radiolabeled Zevalin
Proteomics Moves From the Laboratory to Clinical Research
Radiotherapy Not Needed in Older Lumpectomy Patients With Early Cancer
Raltitrexed + Oxaliplatin for Advanced Colorectal Cancer
Mental Fatigue Worries Chemotherapy Patients
Patients Urged to Work With Professionals Against Fatigue
NCI Director Resigns to Head New Scientific Institute
Combined PET/CT Aids in Head and Neck Cancer Management
MRI Method Predicts Early Response
New Cellular Target Shows Promise in Cancer Treatment
ACR Protests Proposed Diagnostic Mammography Reimbursement Rates
High-Volume Hospitals Better for Some Cancer Surgeries

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Related Content
Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer

Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer

Tim Cortese
April 15th 2025
Article

The addition of chemotherapy to radiotherapy did not show significant improvements in OS when compared with radiotherapy alone in patients with intermediate-risk cervical cancer.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Tisotumab Vedotin Earns Japanese Approval in Advanced Cervical Cancer

Tisotumab Vedotin Earns Japanese Approval in Advanced Cervical Cancer

Tim Cortese
March 28th 2025
Article

Tisotumab vedotin elicited a median OS of 11.5 months vs 9.5 months with chemotherapy in advanced cervical cancer in the phase 3 innovaTV 301 trial.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

Vulvar Cancer Survival Discrepancies Seen in Year 1 of COVID-19 Pandemic

Roman Fabbricatore
March 19th 2025
Article

Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

Patients who had recurrence in the radiation field experienced similar responses vs those with recurrence outside the radiation field.

Immunotherapy Sustains Responses in Radiated Endometrial/Cervical Cancer

Roman Fabbricatore
March 18th 2025
Article

Patients who had recurrence in the radiation field experienced similar responses vs those with recurrence outside the radiation field.